Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Immune Design Corp. (IMDZ) Create: Alert

All | News | Filings
Date FiledTypeDescription
04/02/2019 8-K Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta...
Docs: "Amended and Restated Certificate of Incorporation of Immune Design Corp",
"Amended and Restated Bylaws of Immune Design Corp"
02/21/2019 8-K Quarterly results
01/08/2019 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/13/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
11/06/2018 8-K Quarterly results
Docs: "Immune Design Reports Third Quarter 2018 Financial Results and Provides Corporate Update – Conference call at 1:30 pm Pacific today"
10/11/2018 8-K Quarterly results
09/04/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
07/27/2018 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
07/18/2018 8-K Other Events
06/15/2018 8-K Submission of Matters to a Vote of Security Holders
05/02/2018 8-K Quarterly results
Docs: "Immune Design Reports First Quarter 2018 Financial Results and Provides Corporate Update • The higher dose of CMB305 was deemed safe and cleared for the pivotal Phase 3 • The 20ug dose of G100 shows a two-fold increase in TILs, higher than that seen at the 10ug dose • Conference call at 1:30 pm Pacific today"
03/14/2018 8-K Quarterly results
Docs: "Immune Design Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update – New positive clinical and translational data for both lead agents – Strong balance sheet with 2017 year-end cash and equivalents of $144.2 Million – Conference call at 1:30 pm Pacific today"
12/13/2017 8-K Other Events, Financial Statements and Exhibits
Docs: "Combination of G100 with KEYTRUDA Triggers Robust Systemic Responses in Follicular NHL Patients"
11/01/2017 8-K Quarterly results
Docs: "Immune Design Reports Third Quarter 2017 Financial Results and Provides Corporate Update Company conference call at 1:30 p.m. PT today"
10/25/2017 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "FORM 8-K",
"Underwriting Agreement, between the Company and the Underwriters named therein",
"Opinion of Cooley LLP",
"Immune Design Announces Proposed Public Offering of Common Stock",
"Immune Design Prices $80.0 Million Public Offering of Common Stock"
10/23/2017 8-K Other Events, Financial Statements and Exhibits
Docs: "Updated Business Disclosure",
"Updated Business Disclosure"
10/16/2017 8-K Quarterly results
09/08/2017 8-K Quarterly results
08/30/2017 8-K Quarterly results
08/02/2017 8-K Quarterly results
Docs: "Immune Design Reports Second Quarter 2017 Financial Results and Provides Corporate Update Company conference call at 1:30 p.m. PT today"
07/03/2017 8-K Form 8-K - Current report
06/15/2017 8-K Form 8-K - Current report
05/17/2017 8-K Form 8-K - Current report
03/07/2017 8-K Form 8-K - Current report
03/03/2017 8-K/A Form 8-K/A - Current report [Amend]
01/10/2017 8-K Form 8-K - Current report
12/16/2016 8-K Form 8-K - Current report
11/09/2016 8-K Form 8-K - Current report
10/21/2016 8-K Entry into a Material Definitive Agreement, Other Events
09/16/2016 8-K Form 8-K - Current report
09/14/2016 8-K Other Events, Financial Statements and Exhibits
Docs: "Updated Business Disclosure"
08/09/2016 8-K Quarterly results
Docs: "Immune Design Reports Second Quarter 2016 Financial Results and Provides Corporate Update Company conference call at 1:30 p.m. PT today"
07/01/2016 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
06/20/2016 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Immune Design Appoints Susan L. Kelley, M.D. to Board of Directors"
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy